APA (7th ed.) Citation

N, D., KJ, S., C, B., Y, H., E, B., B, M., . . . IF, H. (2023). A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma. Cancer immunology, immunotherapy : CII, 72(7), 2267. https://doi.org/10.1007/s00262-023-03400-y

Chicago Style (17th ed.) Citation

N, Dasyam, et al. "A Randomised Controlled Trial of Long NY-ESO-1 Peptide-pulsed Autologous Dendritic Cells with or Without Alpha-galactosylceramide in High-risk Melanoma." Cancer Immunology, Immunotherapy : CII 72, no. 7 (2023): 2267. https://doi.org/10.1007/s00262-023-03400-y.

MLA (9th ed.) Citation

N, Dasyam, et al. "A Randomised Controlled Trial of Long NY-ESO-1 Peptide-pulsed Autologous Dendritic Cells with or Without Alpha-galactosylceramide in High-risk Melanoma." Cancer Immunology, Immunotherapy : CII, vol. 72, no. 7, 2023, p. 2267, https://doi.org/10.1007/s00262-023-03400-y.